{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:50Z","timestamp":1784092070802,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>KRAS G12C mutations are rare in intrahepatic cholangiocarcinoma (iCCA), occurring in approximately 1% of cases. While adagrasib has shown efficacy in biliary tract cancers in clinical trials, real-world evidence for sotorasib remains limited. We report a 64-year-old male with advanced iCCA harboring a KRAS p.(G12C) mutation (58.07% allelic frequency) who progressed on multiple prior therapies including chemotherapy, immunotherapy, and targeted therapy. Disease progression was complicated by obstructive jaundice and the Eastern Cooperative Oncology Group (ECOG) performance status deterioration to 3, requiring percutaneous transhepatic cholangiodrainage (PTCD). Following initiation of sotorasib 480\u2009mg daily, the patient achieved a marked partial radiographic response within 6\u2009weeks. CA19-9 normalized, jaundice resolved, PTCD was removed, and performance status improved to ECOG 1. The patient received continuous sotorasib for 10\u2009months, with the initial partial response lasting 8\u2009months with no significant treatment-related adverse events. This case provides real-world evidence that sotorasib can induce durable responses in chemotherapy-refractory, KRAS G12C-mutant iCCA, including in patients with poor performance status and obstructive jaundice who would typically be excluded from clinical trials.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag260","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:05:12Z","timestamp":1783335912000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable response to sotorasib in\n                    <i>KRAS G12C<\/i>\n                    -mutant intrahepatic cholangiocarcinoma: a case report"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-3312","authenticated-orcid":false,"given":"Chaoxing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjian","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2026071500470991300_oyag260-B1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"2026071500470991300_oyag260-B2","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026071500470991300_oyag260-B3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2026071500470991300_oyag260-B4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026071500470991300_oyag260-B5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071500470991300_oyag260-B6","first-page":"4080","article-title":"Final overall survival efficacy results of ivosidenib in patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 ClarIDHy trial","volume":"39","author":"Zhu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026071500470991300_oyag260-B7","first-page":"997","article-title":"Zanidatamab in HER2-amplified biliary tract cancer: results from a phase 2b study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026071500470991300_oyag260-B8","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","article-title":"KRAS: from undruggable to a druggable cancer target","volume":"89","author":"Uprety","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026071500470991300_oyag260-B9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2026071500470991300_oyag260-B10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071500470991300_oyag260-B11","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in patients with KRAS G12C-mutated advanced biliary tract cancer: Results from the KRYSTAL-1 study","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026071500470991300_oyag260-B12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"2026071500470991300_oyag260-B13","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071500470991300_oyag260-B14","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-01315","article-title":"Standard versus reduced sotorasib dosing in KRAS G12C-Mutated Non-Small cell lung cancer: a systematic review and meta-analysis\u2013Have we answered the dosing question?","author":"Aung","year":"2026","journal-title":"JCO Oncol Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag260\/68700567\/oyag260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag260\/68700567\/oyag260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag260\/68700567\/oyag260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:29Z","timestamp":1784090849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag260\/8725342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag260","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,6]]},"article-number":"oyag260"}}